# STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)

Study · id `cardio:ct-nct01927068` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01927068](<https://clinicaltrials.gov/study/NCT01927068>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01927068

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.

## Technical summary

Registry record NCT01927068. Non-randomized; no masking; primary purpose treatment. Start 2013-07 (actual); primary completion 2020-08 (actual). Results posted on 2022-03-15.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 499 participants (enrolled count; ClinicalTrials.gov record NCT01927068, source copy `cardio:ctgov-nct01927068-2023-03-24`, retrieved 2026-10-31)
- Started: 2013-07 (actual) (ClinicalTrials.gov record NCT01927068, source copy `cardio:ctgov-nct01927068-2023-03-24`, retrieved 2026-10-31)
- Primary completion: 2020-08 (actual) (ClinicalTrials.gov record NCT01927068, source copy `cardio:ctgov-nct01927068-2023-03-24`, retrieved 2026-10-31)
- Completion: 2022-08 (actual) (ClinicalTrials.gov record NCT01927068, source copy `cardio:ctgov-nct01927068-2023-03-24`, retrieved 2026-10-31)
- Results first posted: 2022-03-15 (ClinicalTrials.gov record NCT01927068, source copy `cardio:ctgov-nct01927068-2023-03-24`, retrieved 2026-10-31)
- Countries: Australia; Austria; Belgium; France; Germany; Italy; New Zealand; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT01927068, source copy `cardio:ctgov-nct01927068-2023-03-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01927068-2023-03-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
- Acronym: ILLUMENATE
- Condition: Peripheral Arterial Disease
- Intervention (Device): Stellarex 0.035" Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
- Lead sponsor: Spectranetics Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Spectranetics Corporation (`cardio:org-spectranetics-corporation`)

## Provenance

Content hash: faf8d13941f83e2b09b945b893bdb38e41098bf5c2474960e2a477f08a9c8a0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
